Yan Chen

发表

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

W. Isaacs, Jun Luo, A. D. De Marzo, 2014, The New England journal of medicine.

Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms

K. Pienta, P. Nelson, Jun Luo, 2018, The Journal of urology.

Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer

Z. Shao, Yan Chen, Yi Xiao, 2022, Journal of Translational Medicine.

Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.

Parvez M Lokhandwala, Stacy L Riel, Lisa M Haley, 2017, The Journal of molecular diagnostics : JMD.

Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma

Yan Chen, Qi Zhou, Lingjun Chen, 2022, Frontiers in Oncology.

Phenotypic and biochemical characteristics and molecular basis in 36 Chinese patients with androgen receptor variants

Yuanping Shi, Yan Chen, Huaidong Song, 2021, Orphanet Journal of Rare Diseases.

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

W. Isaacs, Jun Luo, E. Antonarakis, 2018, European urology.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Jun Luo, E. Antonarakis, M. Carducci, 2015, JAMA oncology.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

K. Pienta, Jun Luo, E. Antonarakis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

S. Gregory, H. Scher, Jun Luo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MP52-10 RNA SEQUENCING OF CIRCULATING TUMOR CELLS FROM MEN WITH CASTRATION-RESISTANT PROSTATE CANCER

Jun Luo, E. Antonarakis, Changxue Lu, 2014 .

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

M. Harrison, H. Scher, Jun Luo, 2020, JCO precision oncology.

AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).

W. Isaacs, Jun Luo, A. Marzo, 2015 .

Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).

Hao Wang, W. Isaacs, Jun Luo, 2014 .

AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.

K. Pienta, Jun Luo, E. Antonarakis, 2016 .

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

W. Isaacs, Jun Luo, E. Antonarakis, 2018, European urology.